TY - JOUR
T1 - Exploring Functional Differences between the Right and Left Ventricles to Better Understand Right Ventricular Dysfunction
AU - Bernal-Ramirez, Judith
AU - Diaz-Vesga, Magda C.
AU - Talamilla, Matias
AU - Mendez, Andrea
AU - Quiroga, Clara
AU - Garza-Cervantes, Javier A.
AU - Lazaro-Alfaro, Anay
AU - Jerjes-Sanchez, Carlos
AU - Henriquez, Mauricio
AU - Garcia-Rivas, Gerardo
AU - Pedrozo, Zully
N1 - Publisher Copyright:
© 2021 Judith Bernal-Ramirez et al.
PY - 2021
Y1 - 2021
N2 - The right and left ventricles have traditionally been studied as individual entities. Furthermore, modifications found in diseased left ventricles are assumed to influence on right ventricle alterations, but the connection is poorly understood. In this review, we describe the differences between ventricles under physiological and pathological conditions. Understanding the mechanisms that differentiate both ventricles would facilitate a more effective use of therapeutics and broaden our knowledge of right ventricle (RV) dysfunction. RV failure is the strongest predictor of mortality in pulmonary arterial hypertension, but at present, there are no definitive therapies directly targeting RV failure. We further explore the current state of drugs and molecules that improve RV failure in experimental therapeutics and clinical trials to treat pulmonary arterial hypertension and provide evidence of their potential benefits in heart failure.
AB - The right and left ventricles have traditionally been studied as individual entities. Furthermore, modifications found in diseased left ventricles are assumed to influence on right ventricle alterations, but the connection is poorly understood. In this review, we describe the differences between ventricles under physiological and pathological conditions. Understanding the mechanisms that differentiate both ventricles would facilitate a more effective use of therapeutics and broaden our knowledge of right ventricle (RV) dysfunction. RV failure is the strongest predictor of mortality in pulmonary arterial hypertension, but at present, there are no definitive therapies directly targeting RV failure. We further explore the current state of drugs and molecules that improve RV failure in experimental therapeutics and clinical trials to treat pulmonary arterial hypertension and provide evidence of their potential benefits in heart failure.
UR - http://www.scopus.com/inward/record.url?scp=85115049544&partnerID=8YFLogxK
U2 - 10.1155/2021/9993060
DO - 10.1155/2021/9993060
M3 - Article
C2 - 34497685
AN - SCOPUS:85115049544
SN - 1942-0900
VL - 2021
JO - Oxidative Medicine and Cellular Longevity
JF - Oxidative Medicine and Cellular Longevity
M1 - 9993060
ER -